Seed Wealth Management Inc. Cuts Stake in Johnson & Johnson (NYSE:JNJ)

Seed Wealth Management Inc. decreased its stake in Johnson & Johnson (NYSE:JNJ) by 3.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,522 shares of the company’s stock after selling 130 shares during the period. Seed Wealth Management Inc.’s holdings in Johnson & Johnson were worth $556,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of JNJ. Dempze Nancy E raised its stake in shares of Johnson & Johnson by 0.7% in the 3rd quarter. Dempze Nancy E now owns 23,295 shares of the company’s stock valued at $3,628,000 after purchasing an additional 155 shares in the last quarter. Waverly Advisors LLC boosted its holdings in shares of Johnson & Johnson by 153.3% in the 3rd quarter. Waverly Advisors LLC now owns 53,016 shares of the company’s stock valued at $8,257,000 after buying an additional 32,084 shares during the period. United Services Automobile Association grew its position in shares of Johnson & Johnson by 0.5% during the 3rd quarter. United Services Automobile Association now owns 691,445 shares of the company’s stock valued at $107,693,000 after buying an additional 3,522 shares during the last quarter. First Business Financial Services Inc. lifted its holdings in Johnson & Johnson by 2.8% in the third quarter. First Business Financial Services Inc. now owns 10,723 shares of the company’s stock worth $1,670,000 after acquiring an additional 287 shares during the last quarter. Finally, Fusion Capital LLC boosted its stake in Johnson & Johnson by 5.9% in the third quarter. Fusion Capital LLC now owns 32,453 shares of the company’s stock valued at $5,055,000 after acquiring an additional 1,800 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the company. The Goldman Sachs Group initiated coverage on Johnson & Johnson in a report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price target on the stock. Morgan Stanley cut their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price objective for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 22nd. Finally, Bank of America cut their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Eight research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $174.07.

Johnson & Johnson Stock Up 0.0 %

JNJ opened at $145.87 on Friday. The stock’s fifty day moving average is $148.17 and its 200-day moving average is $154.19. Johnson & Johnson has a one year low of $143.13 and a one year high of $175.97. The company has a market capitalization of $351.06 billion, a PE ratio of 9.09, a P/E/G ratio of 2.44 and a beta of 0.53. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. During the same period in the prior year, the company earned $2.68 EPS. Johnson & Johnson’s revenue was up 2.3% on a year-over-year basis. On average, equities analysts predict that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.40%. Johnson & Johnson’s payout ratio is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.